SCS Platform Expansion Leverage Clearside's expanding SCS Microinjector pipeline and ongoing development of small molecule candidates to identify partnerships or licensing deals with ophthalmic companies seeking targeted, non-surgical back-of-the-eye delivery capabilities.

In-Office Delivery Advantage Position to win collaborations emphasizing in-office, repeatable suprachoroidal delivery as a differentiator for therapies addressing macula, retina, or choroid diseases, potentially reducing surgical risks and improving patient access.

Strategic Partnerships Target biotech and pharma firms with in-house investigational therapies that could benefit from SCS delivery, proposing co-development or platform licensing to accelerate timelines and expand addressable indications.

Clinical & Event Visibility Capitalize on active engagement with major ophthalmology conferences (ARVO, EURETINA) and virtual forums to secure speaker slots, sponsor opportunities, and pipeline visibility to potential collaborators and investors.

Financial & Alignment Highlight existing funding and modest revenue baseline to potential partners as a risk-sharing entry point for collaborations, license deals, or milestone-based arrangements aligned with Clearside’s growth trajectory.